Roth Capital Reiterates Buy on LeMaitre Vascular, Raises Price Target to $117
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from $108 to $117.
Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from $108 to $117.